Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
ACCD Stock Summary
Top 10 Correlated ETFs
ACCD
In the News
Chesapeake Bank receives AARP accolade for combatting financial exploitation
Chesapeake Financial Shares Inc. (OTCQX:CPKF)'s Chesapeake Bank was honored by the American Association of Retired Persons (AARP) for its steadfast efforts in combatting financial exploitation. On March 6, AARP revealed the recognition of Chesapeake Bank among a cohort of 166 banks, credit unions, and financial advisory firms bestowed with the prestigious BankSafe Trained Seal.
Accolade To Present at Upcoming Investor Conferences
SEATTLE, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will be presenting at the following upcoming investor conferences:
Alabama's Fertility Ruling Raises Challenges for Stocks of Fertility Benefits Providers
This week brought another blow for reproductive rights in the U.S. An Alabama Supreme Court handed down a ruling that not only can frozen embryos be classified as “children,” but destroying them can lead to charges of wrongful death. This decision has prompted the University of Alabama at Birmingham, the state's largest healthcare provider, to cease all in vitro fertilization (IVF) treatments.
Does Accolade (ACCD) Have the Potential to Rally 25.58% as Wall Street Analysts Expect?
The consensus price target hints at a 25.6% upside potential for Accolade (ACCD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
4 Top Stocks That Flaunt Solid Earnings Acceleration
Invest in stocks such as AxoGen (AXGN), Western Digital (WDC), Accolade (ACCD) and Credo Technology (CRDO) for superb earnings acceleration.
Wall Street Analysts Predict a 26.85% Upside in Accolade (ACCD): Here's What You Should Know
The consensus price target hints at a 26.9% upside potential for Accolade (ACCD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Why Accolade (ACCD) Stock Might be a Great Pick
Accolade (ACCD) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Accolade: Remain Confident That FY25 Guided Growth Is Achievable
I continue to recommend a buy rating with a projected 20% growth in FY25. Recent results show that Accolade beat consensus estimates for revenue and EBITDA, and management expects 20% revenue growth and 2-4% EBITDA margins in FY25. Tailwinds for growth include strong demand for navigation solutions, the health plan channel strategy, GLP-1 growth catalyst, and the recovery in demand for expert medical opinion.
Accolade To Present at Upcoming Investor Conferences
SEATTLE, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will be presenting at the following upcoming investor conferences:
Is Accolade (ACCD) Stock Outpacing Its Business Services Peers This Year?
Here is how Accolade (ACCD) and Adecco SA (AHEXY) have performed compared to their sector so far this year.
ACCD Financial details
ACCD Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-02-28
Metric | History | 2019-02-28 | 2020-02-29 | 2021-02-28 | 2022-02-28 | 2023-02-28 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 2.74 | 3.83 | 5.8 | 4.86 | 5.1 | |
Net income per share | -1.63 | -1.48 | -1.72 | -1.93 | -6.45 | |
Operating cash flow per share | -0.48 | -0.99 | -0.86 | -0.98 | -0.57 | |
Free cash flow per share | -0.57 | -1.08 | -0.94 | -1.03 | -0.67 | |
Cash per share | 1.23 | 2.43 | 14.77 | 5.73 | 4.51 | |
Book value per share | -6.66 | -0.69 | 13.31 | 13.41 | 6.65 | |
Tangible book value per share | -6.66 | -0.86 | 13.15 | 0.52 | -0.11 | |
Share holders equity per share | -6.66 | -0.69 | 13.31 | 13.41 | 6.65 | |
Interest debt per share | 0.63 | 2.17 | 0.13 | 5.06 | 4.45 | |
Market cap | 19.05M | 19.05M | 1.38B | 1.15B | 791.74M | |
Enterprise value | -4.45M | 7.04M | 948.88M | 1.1B | 787.45M | |
P/E ratio | -0.34 | -0.37 | -27.3 | -9.32 | -1.72 | |
Price to sales ratio | 0.2 | 0.14 | 8.12 | 3.7 | 2.18 | |
POCF ratio | -1.15 | -0.56 | -54.8 | -18.4 | -19.45 | |
PFCF ratio | -0.97 | -0.51 | -50.11 | -17.39 | -16.52 | |
P/B Ratio | -0.08 | -0.8 | 3.54 | 1.34 | 1.67 | |
PTB ratio | -0.08 | -0.8 | 3.54 | 1.34 | 1.67 | |
EV to sales | -0.05 | 0.05 | 5.57 | 3.55 | 2.17 | |
Enterprise value over EBITDA | 0.1 | -0.18 | -24.51 | -8.56 | 4.32 | |
EV to operating cash flow | 0.27 | -0.21 | -37.61 | -17.66 | -19.35 | |
EV to free cash flow | 0.23 | -0.19 | -34.38 | -16.69 | -16.43 | |
Earnings yield | -2.97 | -2.7 | -0.04 | -0.11 | -0.58 | |
Free cash flow yield | -1.03 | -1.97 | -0.02 | -0.06 | -0.06 | |
Debt to equity | -0.08 | -3.04 | 0 | 0.37 | 0.67 | |
Debt to assets | 0.3 | 0.58 | 0 | 0.25 | 0.35 | |
Net debt to EBITDA | 0.53 | 0.3 | 11.21 | 0.36 | -0.02 | |
Current ratio | 0.83 | 1.43 | 5.74 | 3.66 | 3.06 | |
Interest coverage | -22.74 | -16.48 | -12.56 | -58.91 | 532.93 | |
Income quality | 0.29 | 0.67 | 0.5 | 0.51 | 0.09 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.21 | 0.2 | 0.19 | 0.32 | 0.22 | |
Research and developement to revenue | 0.38 | 0.32 | 0.29 | 0.27 | 0.28 | |
Intangibles to total assets | 0 | 0.05 | 0.01 | 0.64 | 0.53 | |
Capex to operating cash flow | 0.19 | 0.1 | 0.09 | 0.06 | 0.18 | |
Capex to revenue | -0.03 | -0.03 | -0.01 | -0.01 | -0.02 | |
Capex to depreciation | -0.33 | -0.39 | -0.29 | -0.08 | -0.16 | |
Stock based compensation to revenue | 0.06 | 0.05 | 0.06 | 0.24 | 0.2 | |
Graham number | 15.63 | 4.79 | 22.72 | 24.14 | 31.06 | |
ROIC | 0.26 | -1 | -0.12 | -0.13 | 0.16 | |
Return on tangible assets | -0.86 | -0.43 | -0.11 | -0.27 | -1.09 | |
Graham Net | -7.3 | -1.79 | 12.23 | -0.62 | -1.21 | |
Working capital | -9.78M | 30.14M | 374.91M | 297.38M | 246.54M | |
Tangible asset value | -230.62M | -29.84M | 386.23M | 33.21M | -7.61M | |
Net current asset value | -249.5M | -48.09M | 369.32M | -20.6M | -63.33M | |
Invested capital | -0.08 | -3.04 | 0 | 0.37 | 0.67 | |
Average receivables | 3.7M | 812.5K | 6.51M | 21.32M | 28.75M | |
Average payables | 2.04M | 3.86M | 6.33M | 7.61M | 9M | |
Average inventory | 722K | 1.28M | 1.98M | 2.66M | 3.52M | |
Days sales outstanding | 1.68 | 3.28 | 25.36 | 36.26 | 26.83 | |
Days payables outstanding | 14.79 | 26.12 | 28.8 | 16.92 | 18.63 | |
Days of inventory on hand | 5.47 | 8.16 | 8.97 | 6.51 | 7.38 | |
Receivables turnover | 217.46 | 111.44 | 14.39 | 10.07 | 13.6 | |
Payables turnover | 24.68 | 13.97 | 12.68 | 21.57 | 19.59 | |
Inventory turnover | 66.7 | 44.74 | 40.67 | 56.06 | 49.45 | |
ROE | 0.24 | 2.16 | -0.13 | -0.14 | -0.97 | |
Capex per share | -0.09 | -0.1 | -0.08 | -0.06 | -0.1 |
Quarterly Fundamentals Overview
Last date of statement is 2023-11-30 for Q3
Metric | History | 2022-11-30 | 2023-02-28 | 2023-05-31 | 2023-08-31 | 2023-11-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 1.28 | 1.37 | 1.27 | 1.28 | 1.31 | |
Net income per share | -0.56 | -0.42 | -0.52 | -0.43 | -0.28 | |
Operating cash flow per share | -0.07 | -0.04 | -0.26 | -0.11 | 0.07 | |
Free cash flow per share | -0.09 | -0.07 | -0.31 | -0.15 | 0.02 | |
Cash per share | 4.57 | 4.45 | 4.14 | 3.87 | 3.02 | |
Book value per share | 6.82 | 6.57 | 6.21 | 5.8 | 5.71 | |
Tangible book value per share | -0.08 | -0.11 | -0.23 | -0.32 | -0.24 | |
Share holders equity per share | 6.82 | 6.57 | 6.21 | 5.8 | 5.71 | |
Interest debt per share | 4.47 | 4.38 | 4.32 | 4.18 | 3.2 | |
Market cap | 628.95M | 800.75M | 881.09M | 1.02B | 664.7M | |
Enterprise value | 621.46M | 796.47M | 893.62M | 1.04B | 676.38M | |
P/E ratio | -3.94 | -6.58 | -5.73 | -7.76 | -7.89 | |
Price to sales ratio | 6.92 | 8.09 | 9.45 | 10.51 | 6.69 | |
POCF ratio | -134.05 | -312.92 | -45.68 | -126.69 | 127.7 | |
PFCF ratio | -95.25 | -161.05 | -38.88 | -89.93 | 445.21 | |
P/B Ratio | 1.29 | 1.69 | 1.94 | 2.33 | 1.53 | |
PTB ratio | 1.29 | 1.69 | 1.94 | 2.33 | 1.53 | |
EV to sales | 6.83 | 8.04 | 9.59 | 10.74 | 6.81 | |
Enterprise value over EBITDA | -21.59 | -40.72 | -31.93 | -42.64 | -81.59 | |
EV to operating cash flow | -132.45 | -311.24 | -46.33 | -129.37 | 129.95 | |
EV to free cash flow | -94.12 | -160.19 | -39.43 | -91.83 | 453.03 | |
Earnings yield | -0.06 | -0.04 | -0.04 | -0.03 | -0.03 | |
Free cash flow yield | -0.01 | -0.01 | -0.03 | -0.01 | 0 | |
Debt to equity | 0.65 | 0.67 | 0.69 | 0.72 | 0.56 | |
Debt to assets | 0.35 | 0.35 | 0.36 | 0.37 | 0.31 | |
Net debt to EBITDA | 0.26 | 0.22 | -0.45 | -0.88 | -1.41 | |
Current ratio | 3.14 | 3.06 | 3.09 | 3.08 | 2.35 | |
Interest coverage | -104.62 | 31.16 | -43.03 | -20.54 | -18.6 | |
Income quality | 0.12 | 0.08 | 0.5 | 0.24 | -0.25 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.22 | 0.2 | 0.17 | 0.17 | 0.16 | |
Research and developement to revenue | 0.27 | 0.24 | 0.28 | 0.26 | 0.24 | |
Intangibles to total assets | 0.54 | 0.53 | 0.54 | 0.54 | 0.58 | |
Capex to operating cash flow | 0.41 | 0.94 | 0.18 | 0.41 | -0.71 | |
Capex to revenue | -0.02 | -0.02 | -0.04 | -0.03 | -0.04 | |
Capex to depreciation | -0.16 | -0.21 | -0.29 | -0.3 | -0.33 | |
Stock based compensation to revenue | 0.2 | 0.18 | 0.15 | 0.16 | 0.16 | |
Graham number | 9.27 | 7.9 | 8.56 | 7.53 | 5.96 | |
ROIC | -0.05 | -0.04 | -0.05 | -0.05 | -0.04 | |
Return on tangible assets | -0.09 | -0.07 | -0.09 | -0.08 | -0.06 | |
Graham Net | -1.21 | -1.2 | -1.33 | -1.37 | -1.3 | |
Working capital | 249.62M | 246.54M | 235.74M | 227.26M | 156.42M | |
Tangible asset value | -5.81M | -7.61M | -16.84M | -24.24M | -18.02M | |
Net current asset value | -61.61M | -63.33M | -73.06M | -80.42M | -78.66M | |
Invested capital | 0.65 | 0.67 | 0.69 | 0.72 | 0.56 | |
Average receivables | 27.4M | 25.44M | 26.5M | 25.81M | 25.44M | |
Average payables | 10.54M | 10.07M | 7.81M | 6.28M | 9.88M | |
Average inventory | -1.85M | 160K | 3.98M | 4.2M | 4.47M | |
Days sales outstanding | 23.93 | 24.26 | 25.39 | 23.52 | 23.15 | |
Days payables outstanding | 17.83 | 17.9 | 9.07 | 11.55 | 20.91 | |
Days of inventory on hand | -6.61 | 7.09 | 6.53 | 7.28 | 7.37 | |
Receivables turnover | 3.76 | 3.71 | 3.54 | 3.83 | 3.89 | |
Payables turnover | 5.05 | 5.03 | 9.93 | 7.79 | 4.3 | |
Inventory turnover | -13.62 | 12.69 | 13.78 | 12.36 | 12.22 | |
ROE | -0.08 | -0.06 | -0.08 | -0.08 | -0.05 | |
Capex per share | -0.03 | -0.03 | -0.05 | -0.04 | -0.05 |
ACCD Frequently Asked Questions
What is Accolade, Inc. stock symbol ?
Accolade, Inc. is a US stock , located in Plymouth meeting of Pa and trading under the symbol ACCD
Is Accolade, Inc. buy or a sell ?
15 stock analysts have 15 predictions with a medium analyst target price of $19.42. The lowest prediction is $8 and the highest is $52
What is ACCD stock prediction ?
What is Accolade, Inc. stock quote today ?
Accolade, Inc. stock price is $9.99 today.
Is Accolade, Inc. stock public?
Yes, Accolade, Inc. is a publicly traded company.